Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers

Gelijkaardige items

• Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
  door: Hellmann, Matthew D., et al.
  Gepubliceerd in: (2013)
• Phase II Study of Docetaxel and Vinorelbine as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancers
  door: Chaft, Jamie E., et al.
  Gepubliceerd in: (2013)
• Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
  door: Johnson, Melissa L., et al.
  Gepubliceerd in: (2011)
• Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
  door: Rizvi, Naiyer A., et al.
  Gepubliceerd in: (2011)
• Pack Years of Cigarette Smoking as a Prognostic Factor in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
  door: Janjigian, Yelena Y., et al.
  Gepubliceerd in: (2010)